# Acelarin First Line Randomised Pancreatic Study

> **NCT03610100** · PHASE2,PHASE3 · SUSPENDED · sponsor: **The Clatterbridge Cancer Centre NHS Foundation Trust** · enrollment: 328 (estimated)

## Conditions studied

- Pancreatic Acinar Carcinoma
- Pancreatic Neoplasms

## Interventions

- **DRUG:** Acelarin
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT03610100
- **Lead sponsor:** The Clatterbridge Cancer Centre NHS Foundation Trust
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2015-12
- **Primary completion:** 2020-09
- **Final completion:** 2022-12
- **Target enrollment:** 328 (ESTIMATED)
- **Why stopped:** Suspended to recruitment following TSC review on efficacy and toxicities
- **Last updated:** 2019-10-29

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03610100

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03610100, "Acelarin First Line Randomised Pancreatic Study". Retrieved via AI Analytics 2026-07-30 from https://api.ai-analytics.org/clinical/NCT03610100. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*